Compounds for treating ophthalmic diseases and disorders
The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.
1. A method for treating uveitis in a human subject in need thereof with a dihydroorotate dehydrogenase (DHODH) inhibitor compound, wherein the compound is 3-(2,3,5,6-tetrafluoro-3′-trifluoromethoxy-biphenyl-4-ylcarbamoyl)-thiophene-2-carboxylic acid and is represented by the following formula:
comprising the step of administering by intravitreal injection a therapeutically effective amount of the compound.
2. The method of claim 1 , wherein said compound is formulated as a slow release formulation and is administered at least once per month.
3. The method of claim 1 , wherein the compound is formulated with one or more pharmaceutically acceptable excipients therefor.
4. The method of claim 3 , wherein the excipients are selected from the group consisting of hydrophilic polymer excipients, tonicity agents, buffers, sugars, preservatives, solvents and antioxidants.
5. The method of claim 1 , wherein the compound is administered to the posterior segment of the eye.
6. The method of claim 1 , wherein the compound is formulated as a slow release formulation and is administered at least every sixth months.
7. The method of claim 4 , wherein the sugars are selected from the group consisting of sucrose, trehalose, mannose, D-galactose, and lactose.
8. The method of claim 1 , wherein the uveitis being treated is autoimmune uveitis.
9. The method of claim 1 , wherein the dihydroorotate dehydrogenase (DHODH) inhibitor compound is administered by intravitreal injection not more than once per month.